Management of chronic, refractory schizophrenic patients with high-dose loxapine

L. Ereshefsky, S. R. Saklad, T. E. Mings, C. R. Lehmann

    Research output: Contribution to journalArticlepeer-review

    2 Scopus citations

    Abstract

    The authors suggest that schizophrenic patients unresponsive to other antipsychotic agents should be considered for a trial on loxapine. The loxapine dosage should be slowly titrated upward unless rapid tranquilization is indicated. Use of the liquid form of medication is recommended for initiation of routine loxapine therapy to assure compliance during titration. Loxapine has been reported to cause seizures in overdose, justifying careful screening of patients for high-dose loxapine therapy. Double-blind, placebo-controlled trials are needed to verify the superiority of loxapine over other antipsychotic agents.

    Original languageEnglish (US)
    Pages (from-to)600-603
    Number of pages4
    JournalPsychopharmacology bulletin
    Volume19
    Issue number4
    StatePublished - Jan 1 1983

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Management of chronic, refractory schizophrenic patients with high-dose loxapine'. Together they form a unique fingerprint.

    Cite this